An Innovative Long Acting Florfenicol Formulation for the Treatment of Bovine Respiratory Disease
J Embrechts, W Lohlein, O Wolf, M Ocak, J de Busser
14. October 2010
The efficacy in the treatment of acute Bovine Respiratory Disease (BRD) of a novel florfenicol 300mg/ml suspension for injection (Florgane®) given at a single intramuscular (I.M.) dose of 30 or 40mg/kg b.w. was compared in two clinical field studies with that of a commercial florfenicol 300mg/ml solution for injection administered once subcutaneously (S.C.) at 40mg/kg b.w.. Respiratory pathogens isolated were Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis. Single I.M. doses of Florgane® at 30 and 40mg/kg b.w. were equally efficacious with respect to treatment success and relapse rates and both dose regimens were non-inferior to florfenicol 300mg/ml solution for injection administered once S.C. at 40mg/kg b.w.. The efficacy of Florgane® demonstrated at the lower dose of 30mg/kg b.w. is consistent with its high bioavailability and prolonged duration of action after single I.M. administration.
Keywords: Bovine Respiratory Disease, cattle, florfenicol, treatment